S&P Global has upgraded Biocon Biologics' credit rating to 'BB+' from 'BB' following a significant reduction in the company's adjusted debt. This upgrade follows the settlement of a $1 billion CCPS liability to Viatris through a mix of equity and cash, simplifying the capital structure. Adjusted debt is projected to fall to INR 115 billion by FY26 from INR 248 billion in FY25, significantly improving the company's financial health. Analysts expect EBITDA to grow to INR 45 billion by FY27, driven by a 15% growth in the biosimilars segment.

Biocon Limited has completed the acquisition of the final tranche of 7,18,34,691 equity shares of Biocon Biologics Limited (BBL) from Mylan Inc. for USD 200 million. This follows the first tranche completed earlier in January 2026, bringing the total acquisition to 14,36,69,382 shares for a total cash consideration of USD 400 million. Post-acquisition, Biocon's ownership in its material subsidiary BBL has increased to approximately 98% on a fully diluted basis. This consolidation allows Biocon to have near-total control over its biologics business operations and future cash flows.

Biocon Limited has successfully raised Rs 4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP) by issuing 11.26 crore shares at Rs 368.35 per share. The primary purpose of this fundraise is to finance the buyout of Viatris' (Mylan Inc.) stake in Biocon Biologics and to repay debt associated with this acquisition and Edelweiss CCDs. This strategic move will make Biocon Biologics a 100% wholly owned subsidiary by March 31, 2026. The QIP attracted 39 institutional investors, including major names like SBI Mutual Fund, ICICI Prudential, and JPMorgan.

Biocon Limited has successfully completed a Qualified Institutional Placement (QIP), raising ₹41,500 million (₹4,150 crore) to strengthen its financial position. The company allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share, representing a significant capital infusion. Major institutional investors including SBI Mutual Fund and ICICI Prudential Mutual Fund participated heavily, each taking up nearly 29.5% of the total issue. This fundraise results in an equity dilution of approximately 7.47% as the total share count increases to 162.09 crore shares.

Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) on January 14, 2026, raising approximately ₹4,150 crore. The company approved the allocation of 11,26,64,585 equity shares to institutional investors at a final price of ₹368.35 per share. This issue price represents a 5% discount to the regulatory floor price of ₹387.74. The successful closure and institutional participation indicate strong market confidence in the company's growth prospects.

Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) which opened on January 12, 2026. The company's Fund Raising Committee approved the allocation of 11,26,64,585 equity shares to eligible institutional buyers. The issue price was finalized at ₹368.35 per share, representing a total fundraise of approximately ₹4,150 crore. This capital infusion is expected to strengthen the company's balance sheet and support its strategic growth initiatives.

Biocon Limited has successfully closed its Qualified Institutions Placement (QIP) on January 14, 2026. The company approved the allocation of 11,26,64,585 equity shares to qualified institutional buyers at an issue price of ₹368.35 per share. This price represents a 5% discount to the floor price of ₹387.74 per share. The total capital raised through this issue is approximately ₹4,150 crore, which will likely be used to strengthen the balance sheet or fund expansion.

Indian Oil Corporation (IOCL), through its 50:50 joint venture Urja Bharat Pte Limited (UBPL) with Bharat Petroleum, has reported successful oil discoveries in Abu Dhabi's Onshore Block 1. The discoveries include light crude oil from the Shilaif formation in the XN-76 well and the Habshan reservoir in the XN-79 02S well. These findings mark a significant milestone for IOCL's international upstream operations, establishing the presence of unconventional oil resources. The company is now moving into the appraisal phase to determine the economic viability and potential development of these prospects.

Indian Oil Corporation (IOCL) and Maruti Suzuki India Limited (MSIL) have signed a Memorandum of Understanding to establish Maruti Suzuki service facilities at select IOCL fuel stations. This strategic partnership leverages IOCL's vast network of over 41,000 fuel stations to provide periodic maintenance and minor repairs for Maruti Suzuki car owners. The collaboration aims to enhance customer convenience by offering a 'one-stop' solution for refueling and servicing. For MSIL, this expands their existing reach of 5,780+ service touchpoints, while for IOCL, it strengthens non-fuel revenue potential.

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received US FDA approval for its ANDA for Everolimus Tablets for Oral Suspension. The approval covers three dosage strengths: 2 mg, 3 mg, and 5 mg, targeting the treatment of Tuberous Sclerosis Complex (TSC). This product is indicated for both adult and pediatric patients, specifically for those with Subependymal Giant Cell Astrocytoma or TSC-associated seizures. This regulatory milestone strengthens Biocon's vertically integrated drug portfolio in the critical US market.

Music Broadcast Limited (Radio City) has declared an interim dividend of ₹0.01 per Non-Convertible Non-Cumulative Redeemable Preference Share (NCRPS) for FY 2025-26. More significantly, the Board has approved the redemption of these NCRPS at a price of ₹120 per share upon maturity. The record date for determining eligibility for both the dividend and the redemption amount is January 9, 2026. The company has provided detailed instructions regarding TDS and withholding tax requirements for various shareholder categories.

Biocon Biologics is expanding its oncology portfolio with three major biosimilars targeting drugs with combined 2024 sales exceeding $40 billion, including Keytruda and Opdivo. The company is on track to integrate Biocon Biologics as a wholly owned subsidiary by March 31, 2026, to streamline operations and focus on high-growth areas like GLP-1 peptides and insulins. This strategic move targets a $75 billion oncology market opportunity, representing 35% of the global pharmaceutical market. Post-integration, Shreehas Tambe will lead the combined entity as CEO & Managing Director.

Biocon Limited has significantly increased its ownership in its subsidiary, Biocon Biologics Limited (BBL), to approximately 94% on a fully diluted basis. The transaction involved acquiring 26.19 crore BBL shares through a share swap, issuing 17.12 crore new Biocon shares at Rs. 405.78 each to partners including Mylan and Serum Institute. Additionally, the company completed a cash acquisition of 7.18 crore BBL shares from Mylan for USD 200 million. While this consolidates a high-growth asset, it results in an 11.36% equity dilution for existing Biocon shareholders.

Biocon Limited has completed a significant consolidation of its subsidiary, Biocon Biologics Limited (BBL), by acquiring shares from Mylan, Serum Institute, and other partners. The company allotted 17.13 crore equity shares at an issue price of Rs. 405.78 per share, resulting in an 11.36% equity dilution. Additionally, Biocon paid USD 200 million in cash to Mylan for a portion of the stake. Following these transactions, Biocon's ownership in its high-growth biologics arm has increased to approximately 94% on a fully diluted basis.

Biocon Limited has successfully completed the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The total value of the redemption amounts to Rs 500 Crores, with each NCD having a face value of Rs 1,00,000. The payment was executed on January 05, 2026, following Board approval granted in November 2025. This early repayment indicates a strong liquidity position and will likely reduce the company's future interest expenses.

Music Broadcast Limited (Radio City) has approved the redemption of 89,69,597 Non-Convertible Redeemable Preference Shares (NCRPS) as their 36-month term concludes. Each NCRPS will be redeemed at ₹120, which includes the face value of ₹10, an issuance premium of ₹90, and a redemption premium of ₹20. Additionally, the board has declared an interim dividend of 0.1% (₹0.01 per share) on these preference shares for FY 2025-26. The record date for both the dividend and redemption proceeds is fixed as January 9, 2026.

Biocon Limited shareholders have approved all six resolutions proposed at the Extraordinary General Meeting held on December 31, 2025. Key approvals include raising funds through equity or other securities and a preferential issuance of shares for consideration other than cash. Shareholders also authorized an increase in investment and loan limits under Section 186 and cleared material related-party transactions with Mylan Inc. While most resolutions passed with near-unanimous support, the proposal to increase investment limits saw a notable 15.67% dissent from voting participants.

Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.